Home' Australian Pharmacist : Australian Pharmacist June 2016 Contents Australian Pharmacist June 2016 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
COUNSELLING IN PRACTICE
1. Select the CORRECT statement:
a) Physical dependence to opioids is
when a patient has a compulsion to use
b) Psychological dependence is when
patients exhibit extreme behaviour
patterns associated with using or
acquiring opioids, to the extent of
causing damage or harm to physical
and/or psychological and/or social
c) Addiction is when withdrawal
symptoms (e.g. nausea, vomiting,
anxiety, sweating) appear with abrupt
cessation of an opioid that has been
used for an extended period of time.
d) Tolerance to opioids is when
increasingly larger opioid doses are
required to achieve the same level of
2. Select the CORRECT statement in
relation to OTC codeine products:
a) There is conclusive evidence to suggest
combination products containing
8–15 mg of codeine are more effective
than the non-opioid alone.
b) Risk of harm (morbidity, toxicity and
dependence) versus questionable
or low benefit of OTC codeine
combination products led the TGA
Advisory Committee on Medicines
Scheduling to recommend the up-
scheduling of Pharmacist Only codeine
products to Prescription Only.
c) Prolonged use of supratherapeutic
doses of codeine/paracetamol
analgesics can cause adverse effects,
such as upper gastrointestinal
tract ulceration, haemorrhage, and
perforation and renal failure.
d) All the commercially available OTC
codeine preparations contain sufficient
codeine per fixed dose so patients
receive the clinically recommended
dose for analgesic effect when taken
according to manufacturers’ directions.
3. Select the CORRECT statement in
relation to management of persistent
or chronic pain:
a) An estimated 33% of patients (including
children and adolescents) in Australia
live with persistent pain (e.g. back
pain, arthritis, headaches), with the
prevalence increasing to 66% of older
b) The majority of patients with persistent
non-cancer pain can access adequate
care for their pain.
c) Of patients living with persistent
pain, up to 80% of patients could be
managed adequately if they could
access appropriate pain services.
d) There is ample evidence supporting
incremental/sustained benefits of
administering multiple doses of
combination OTC codeine products.
4. Select the CORRECT statement in
relation to the treatment options
available for pain management:
a) Analgesic medicine should be treated as
a panacea for pain.
b) Managing a patient’s emotional
wellbeing is as important as managing
the pain, as many patients with
persistent pain also have a history of
c) There is no need for patients to seek
help from their doctor even if the pain
they are trying to treat has lasted for
more than 12 weeks; or if the injury/
illness that caused the pain has healed
but the pain is still present (persistent
d) There is significant evidence supporting
the use of surgical interventions
(destroying or inactivating nerve tissue)
for non-cancer pain conditions.
5. Pharmacists can play an important
role in helping patients living
with pain. Select the CORRECT
statement about some of the things
pharmacists can do:
a) Help patients understand their pain
condition and pain medicines, and have
realistic expectations of their medicines.
b) Help overcome the stigma surrounding
patients with persistent pain by
showing empathy and respect.
c) Identify patients that may not be
receiving adequate care, and refer
them to appropriate places for more
information and help.
d) All of the above.
Identify patients that need referral;
using the right medicine for the right
type of pain!
1. Rossi S, ed. Australian medicines handbook. Adelaide:
Australian Medicines Handbook; 2016.
2. Analgesic Expert Group. Analgesic, version 6. Melbourne:
Therapeutic Guidelines; 2012.
3. eMIMS cloud. Sydney: MIMS Australia; 2016.
4. Rosenquist E. Definition and pathogenesis of chronic pain.
In: UpToDate. 2015. At: www.uptodate.com
5. Painaustralia. Why we need the national pain strategy.
6. Shaheed C, Maher C, McLachlan A. Investigating the
efficacy and safety of over-the-counter codeine containing
combination analgesics for pain and codeine based
antitussives. 2016. At: www.tga.gov.au/sites/default/
7. Hall T. Management of persistent pain in older people.
Journal of Pharmacy Practice and Research. 2016;46(1):60–
8. Roxburgh A, Hall W, Burns L, et al. Trends and
characteristics of accidental and intentional codeine
overdose deaths in Australia. Med J Aust. 2015;203(7):299–
9. Frei M, Nielsen S, Dobbin M, et al. Serious morbidity
associated with misuse of over-the-counter codeine–
ibuprofen analgesics: a series of 27 cases. Med J Aust.
10. Dobbin M. Pharmaceutical drug misuse in Australia. Aust
11. Therapeutic Goods Administration. Reasons for the
scheduling delegate’s interim decision and invitation for
further comment for the ACMS. 2015. At: www.tga.gov.
12. Therapeutic Goods Administration. Proposal for the
re-scheduling of codeine products. 2016. At: www.tga.
13. Tan SH, Noble C, Lau E, et al. Pharmacist counselling for
patients with persistent pain: patients’ and pharmacists’
perspectives. 16th World Congress on Pain (International
Association for the Study of Pain); 2016 Sep 26–30;
Yokohama, Japan. Submitted.
14. McCaffery M, Beebe A. Pain: clinical manual for nursing
practice. St Louis: C.V. Mosby Company; 1989.
15. Rosenquist E. Overview of the treatment of chronic pain. In:
UpToDate. 2016. At: www.uptodate.com
16. Weissman DE, Haddox JD. Opioid pseudoaddiction - an
iatrogenic syndrome. Pain. 1989;36(3):363–6 .
17. Rosenquist E. Evaluation of chronic pain in adults. In:
UpToDate. 2015. At: www.uptodate.com
18. Tang NYK, Crane C. Suicidality in chronic pain: a review of
the prevalence, risk factors and psychological links. Psychol
Med. 2006;36(5):575–86 .
19. Painaustralia. Getting help and taking action. At: www.
20. Hall T, Seng LSD, Antwertinger Y, et al. We don’t know what
they don’t know: pain medication and manageement
knowledge. 16th World Congress on Pain (International
Association for the Study of Pain); 2016 Sep 26–30;
Yokohama (Japan). Submitted.
21. Painaustralia. Pain clinics. At: www.painaustralia.org.au/
Links Archive Australian Pharmacist May 2016 Australian Pharmacist July 2016 Navigation Previous Page Next Page